The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Sophiris Bio Appoints a New Director to the Board

Friday, November 30, 2012

Sophiris Bio Appoints a New Director to the Board17:00 EST Friday, November 30, 2012SAN DIEGO, CA and VANCOUVER, Nov. 30, 2012 /CNW/ - Sophiris Bio, Inc. (TSX: SHS) today announced the appointment of Noah Knauf as a director of the Company.  Mr. Knauf replaces Jonathan Leff, who has resigned as a director, as a Warburg Pincus nominee director.Mr. Knauf focuses on healthcare and life sciences as an investment professional at Warburg Pincus. He currently serves on the Boards of Directors of Constitution Medical Investors, Home Dialysis Plus, International Technidyne Corporation, Keystone Dental, RegionalCare Hospital Partners and Silk Road Medical. Prior to joining Warburg Pincus, Mr. Knauf was an Associate at Parthenon Capital, a private equity firm, and a consultant with Bain & Company, a global consulting firm. He holds an MBA from Stanford University Graduate School of Business where he was an Arjay Miller Scholar, and earned a Bachelor of Science in Business Administration degree (BSBA) from the University of Arizona.Sophiris Bio would like to thank Jonathan Leff for his service to the board and to the Company.About SophirisSophiris Bio Inc. is a urology company developing a late-stage, highly targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), an unsatisfied market with significant demand. PRX302, the company's product candidate for the symptoms of BPH, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is planning to begin a pivotal trial in the first half of 2013. Sophiris is advised by leading urologists, backed by experienced investors, and led by a team that has achieved more than twenty drug approvals. For more information, please visit www.sophirisbio.com.Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE: Sophiris Bio, Inc.For further information: Lauren Glaser Investor Relations The Trout Group 646-378-2972 lglaser@troutgroup.com James Beesley Investor Relations Sequoia Partners 778-389-7715 james@sequoiapartners.ca Michael Moore Investor Relations TMX Equicom 619-467-7067 mmoore@tmxequicom.com Jason I. Spark Canale Communications, Inc. 619-849-6005 jason@canalecomm.com